Advances in Cell and Gene Therapy

1.7(top 50%)

impact factor

88(top 100%)

papers

360(top 50%)

citations

10(top 50%)

h-index

1.7(top 50%)

impact factor

131

all documents

405

doc citations

17(top 50%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	TRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translation	Advances in Cell and Gene Therapy	2020	85
2	CAR T cells targeting α_vβ₃integrin are effective against advanced cancer in preclinical models	Advances in Cell and Gene Therapy	2018	45
3	Rapid production of clinical‐grade SARS‐CoV‐2 specific T cells	Advances in Cell and Gene Therapy	2020	24
4	Toward “off‐the‐shelf” allogeneic CAR T cells	Advances in Cell and Gene Therapy	2020	20
5	Meeting report: Advances in minimal residual disease testing in multiple myeloma 2018	Advances in Cell and Gene Therapy	2019	19
6	CD276 as a novel CAR NK‐92 therapeutic target for neuroblastoma	Advances in Cell and Gene Therapy	2021	18
7	CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases	Advances in Cell and Gene Therapy	2018	13
8	An in silico analysis of effective siRNAs against COVID‐19 by targeting the leader sequence of SARS‐CoV‐2	Advances in Cell and Gene Therapy	2021	13
9	TRUCKs with IL-18 payload: Toward shaping the immune landscape for a more efficacious CAR T-cell therapy of solid cancer	Advances in Cell and Gene Therapy	2018	11
10	Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics	Advances in Cell and Gene Therapy	2019	11
11	Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells	Advances in Cell and Gene Therapy	2021	10
12	CAR‐T cell therapy for non‐Hodgkin lymphomas: A new treatment paradigm	Advances in Cell and Gene Therapy	2019	8
13	Case report: Impact ofBITEonCAR‐T cell expansion	Advances in Cell and Gene Therapy	2019	7
14	Characteristics of Sweet's syndrome associated with novel acute myeloid leukemia targeted drugs—Midostaurin and Enasidenib	Advances in Cell and Gene Therapy	2019	6
15	Establishing a standardized system for review and adjudication of chronic graft‐vs‐host disease data in accordance with the National Institutes Consensus criteria	Advances in Cell and Gene Therapy	2019	6
16	Important aspects of T‐cell collection by apheresis for manufacturing chimeric antigen receptor T cells	Advances in Cell and Gene Therapy	2020	6
17	Pre- and posttransplant use of mogamulizumab in patients with aggressive adult T-cell leukemia-lymphoma: A statement from key opinion leaders in Japan	Advances in Cell and Gene Therapy	2018	4
18	Targeting reservoirs of HIV replication in lymphoid follicles with cellular therapies to cure HIV	Advances in Cell and Gene Therapy	2019	4
19	When should transplant physicians think about familial blood cancers?	Advances in Cell and Gene Therapy	2019	4
20	T‐cell acute lymphoblastic leukemia: Current approach and future directions	Advances in Cell and Gene Therapy	2019	4
21	Cancer‐associated thrombosis: Where do we stand?	Advances in Cell and Gene Therapy	2020	4
22	Genomic Designs of rAAVs Contribute to Pathological Changes in the Livers and Spleens of Mice	Advances in Cell and Gene Therapy	2022	4
23	Ethical Challenges and Controversies in the Practice and Advancement of Gene Therapy	Advances in Cell and Gene Therapy	2022	4
24	Mesenchymal stromal cell infusions for acute graft-versus-host disease: Rationale, data, and unanswered questions	Advances in Cell and Gene Therapy	2018	3
25	Update on Lymphoma classification: The 2016 revised World Health Organization Classification of Hematopoietic and Lymphoid Neoplasms	Advances in Cell and Gene Therapy	2019	3
26	Viral infections after allogeneic hematopoietic stem cell transplant	Advances in Cell and Gene Therapy	2019	3
27	Biomarker profiling of steroid-resistant chronic GvHD patients undergoing extracorporeal photopheresis demonstrates high ST2 levels at treatment onset and decline during therapy	Advances in Cell and Gene Therapy	2019	3
28	Advances in ex vivo T cell depletion - where do we stand?	Advances in Cell and Gene Therapy	2019	3
29	Prevention of relapse after allogeneic stem cell transplantation in acute myeloid leukemia: Updates and challenges	Advances in Cell and Gene Therapy	2020	3
30	COVID‐19 & allogeneic transplant: Activity and preventive measures for best outcomes in China	Advances in Cell and Gene Therapy	2020	3
31	Immunological tumor heterogeneity and diagnostic profiling for advanced and immune therapies	Advances in Cell and Gene Therapy	2021	3
32	Identification of homologous human miRNAs as antivirals towards COVID‐19 genome	Advances in Cell and Gene Therapy	2021	3
33	Emerging role of CAR T cell therapy in multiple myeloma	Advances in Cell and Gene Therapy	2018	2
34	Double-hit and double-expressor B-cell lymphomas: Current treatment strategies and impact of hematopoietic cell transplantation	Advances in Cell and Gene Therapy	2018	2
35	Method comparison study of peripheral blood CD34⁺ count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified ISHAGE)	Advances in Cell and Gene Therapy	2018	2
36	Hematopoietic stem cell transplantation for T-cell lymphoma	Advances in Cell and Gene Therapy	2018	2
37	Azacitidine as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation	Advances in Cell and Gene Therapy	2019	2
38	The therapeutic role of natural killer cells in multiple myeloma	Advances in Cell and Gene Therapy	2019	2
39	From bench to bedside: Exploiting memory NK cell responses to leukemia	Advances in Cell and Gene Therapy	2019	2
40	The role of autologous stem cell transplantation in diffuse large B‐cell lymphoma	Advances in Cell and Gene Therapy	2019	2
41	High‐dose chemotherapy and autologous transplantation for testicular germ cell tumors	Advances in Cell and Gene Therapy	2019	2
42	Philadelphia chromosome‐like acute lymphocytic leukemia: Perspectives on diagnosis	Advances in Cell and Gene Therapy	2019	2
43	Advances in transplantation and gene therapy in transfusion-dependent β-thalassemia	Advances in Cell and Gene Therapy	2019	2
44	Perspective: Cell therapy, SARS‐CoV‐2, COVID‐19, and James Lind	Advances in Cell and Gene Therapy	2020	2
45	Primary central nervous system lymphoma: Consensus, controversies, and future directions	Advances in Cell and Gene Therapy	2020	2
46	RNA ImmunoGenic Assay: Simple method for detecting immunogenicity of in vitro transcribed mRNA	Advances in Cell and Gene Therapy	2020	2
47	Vaccine Boosting CAR-T Cell Therapy: Current and Future Strategies	Advances in Cell and Gene Therapy	2023	2
48	Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma	Advances in Cell and Gene Therapy	2018	1
49	Does an increased probability of graft‐vs‐host disease improve the survival of patients with adult T‐cell leukemia‐lymphoma? A simulation analysis using a Markov model	Advances in Cell and Gene Therapy	2019	1
50	Advances in measurable residual disease monitoring for adult acute lymphoblastic leukemia	Advances in Cell and Gene Therapy	2019	1

Scientometrics

Overviews

Citing Bodies

Advances in Cell and Gene Therapy

Top Articles